Over a four-week treatment period, multiple outcomes were assessed, including overall clinical efficacy, tinnitus symptom improvement, TCM syndrome scores, THI scores, SAS scores, and PSQI scores
GI issues, gallbladder problems, lean mass loss, and long-term unknowns require thoughtful prescribing and monitoring
Retatrutide's novel triple-agonist approach produced 28.7% weight loss in Phase 3 TRIUMPH-4 (confirming 24.2% in Phase 2) by adding glucagon and GIP receptor activation
Repeated injections in the same site compound trauma to surrounding vessels and increase the likelihood of noticeable discoloration
The b12 intravenous dose and b12 iv dose must be set by doctors